Cosentyx (Secukinumab) for Psoriasis: How IL-17 Inhibitors Control Severity
Cosentyx (secukinumab) is an IL-17 inhibitor that targets a key inflammatory pathway in psoriasis. Discover how it works, how quickly it clears plaques, dosing schedules, clinical benefits, and important safety considerations.
